The United States Patent and Trademark Office just handed Summit Biosciences Inc. a patent that could matter quite a bit in the naloxone market. The newly issued U.S. Patent No. 12,514,854 B2 covers Rezenopy, a 10mg naloxone nasal spray designed for emergency opioid overdose treatment.

Summit, which operates as a subsidiary of Kindeva Drug Delivery L.P., announced Wednesday that the patent takes effect January 6, 2026, and runs through February 5, 2041. That's nearly 16 years of potential market protection for the highest-dose naloxone spray currently approved by regulators.

The Scienture Connection

Here's where it gets interesting for penny stock watchers. Back in March 2025, Scienture LLC, the wholly owned subsidiary of Scienture Holdings Inc. (SCNX), struck a commercialization deal with Summit for exclusive U.S. rights to Rezenopy. The arrangement splits responsibilities in a fairly standard pharmaceutical partnership model.

Summit handles manufacturing and commercial supply. Meanwhile, Scienture takes ownership of the new drug application (pending certain commercial obligations) and manages sales, marketing, and distribution throughout the United States using its existing commercial infrastructure.

The FDA gave Rezenopy its blessing in April 2024, making it the highest-dosage naloxone nasal spray approved for emergency use. That distinction matters when dealing with increasingly potent synthetic opioids flooding illicit drug markets.

Understanding the Product

Rezenopy delivers naloxone hydrochloride as a 10mg nasal spray, functioning as an opioid antagonist for emergency treatment of known or suspected overdoses. It's indicated when respiratory depression or central nervous system depression signals potential opioid involvement, regardless of patient age.

The product is designed for immediate administration in any setting where opioids might be present. Each carton contains two blister packages with single-use spray devices for intranasal administration only.

The newly issued patent qualifies for listing in the FDA's Orange Book, which could provide additional intellectual property protection as Scienture builds out commercial operations. The spray uses the established naloxone hydrochloride molecule and familiar nasal spray delivery method, but packages it at higher concentrations to combat more potent opioid compounds.

Market Opportunity and Company Performance

According to IQVIA data, annual U.S. naloxone sales hit approximately $154 million, with unit volume reaching 9.3 million units. That's a substantial market driven by an unfortunate reality: persistent demand for overdose reversal medications.

Scienture has shown recent operational progress. Third quarter net revenue jumped from roughly $65,000 to $590,000, while gross profit climbed from about $4,000 to $575,000. Those percentage gains look impressive, though the absolute numbers reflect a company still in early commercialization stages.

The company also expanded its product portfolio access in November 2025 when Arbli, an oral suspension formulation of losartan potassium at 10mg/mL, gained formulary placement with major national payors. Coverage now includes multiple commercial plans and Medicare supplement options. Arbli represents the first FDA-approved ready-to-use oral suspension of losartan potassium, targeting patients who need alternatives to tablets or capsules.

Scienture Holdings (SCNX) shares traded up 0.13% at $0.54 during Wednesday's premarket session, hovering near the 52-week low of $0.46.